Replies to post #13919 on Biotech Values

[DewDiligence]

Re: NSTK

Evidently, there’s some support for my anti-Quay sentiments even among NSTK bulls:

http://tinyurl.com/csgse

Until this latest episode, I was on the verge of taking a small position in NSTK based, in part, on the FDA’s consenting to an abbreviated 505(b)(2) timeline for intranasal PTH. But, now, my sentiment toward the company has turned negative again. I don’t see why I should entrust my money to a company where management allows the CEO to front run shareholders so blatantly.